Jaguar Health subsidiary Napo Pharmaceuticals is continuing its global crofelemer development program for rare intestinal failure diseases while preparing for a planned mid-2027 New Drug Application filing for microvillus inclusion disease. Key Investor TakeawaysJaguar Health (NASDAQ:JAGX) continues to target a mid-2027 MVID NDA filing for crofelemer powder for oral solution.
Detailed price information for Jaguar Health Inc (JAGX-Q) from The Globe and Mail including charting and trades.
Gainers Jaguar Health (NASDAQ:JAGX) stock moved upwards by 34.0% to $6.34 during Tuesday's pre-market session. The company's market cap stands at $2.4 million. Option Care Health (NASDAQ:OPCH) stock rose
Jaguar Health shares surged 34.67% after hours Monday following the company’s special dividend announcement and debt-payment extensions.
Napo Pharmaceuticals, a subsidiary of Jaguar Health (NASDAQ:JAGX), said an abstract covering preliminary results from an ongoing study of crofelemer in adults with short bowel syndrome with intestinal failure has been accepted for presentation at the American College of Gastroenterology Annual Scientific Meeting. ACG 2026 is scheduled to take place from October 9 to October 14 in Nashville, Tennessee.
Detailed price information for Jaguar Health Inc (JAGX-Q) from The Globe and Mail including charting and trades.
Jaguar Health is surging on a float so thin that a handful of trades can swing the price wildly, while a rare pediatric disease program edges closer to a pivotal regulatory filing that could either validate the rally or expose how fragile it really is.
Jaguar Health is surging Friday after announcing debt-for-equity exchanges that cut debt by over $6.7 million and retired a promissory note.
Jaguar Health shares are sliding Thursday as equity dilution concerns weigh on the company following a debt-for-equity exchange.
Two biotech stocks are getting crushed while the sector benchmark climbs, and the reasons behind each selloff could not be more different. Understanding what separates a deliberate corporate move from pure micro-cap chaos is the key to reading both situations correctly.
Gainers Artelo Biosciences (NASDAQ:ARTL) shares rose 216.1% to $13.12 during Wednesday's regular session. The market value of their outstanding shares is at $2.2 million. Vistagen Therapeutics (NASDAQ:VTGN) shares
Jaguar Health shares are plunging Wednesday morning as profit-taking reverses an explosive Tuesday rally sparked by regulatory fee waivers.
Gainers IM Cannabis (NASDAQ:IMCC) stock rose 56.3% to $6.47 during Wednesday's pre-market session. The company's market cap stands at $2.5 million. Vistagen Therapeutics (NASDAQ:VTGN) shares increased by
U.S. futures edged higher; InnovAge fell 9.4% after a 10M-share offering. Jaguar Health, Voyager Technologies and other stocks also dropped premarket.
Worthington Enterprises surged 15.9% premarket after beating Q1 EPS and sales estimates; Wheeler REIT led gainers, while Jaguar Health and Biomea fell.
Jaguar Health aims to file for approval of its Crofelemer powder treatment for pediatric MVID in mid-2027.
Endovia Health Sciences shares jumped 47.83% after hours Tuesday as investors cheered fresh funding for its CannEpil drug program.
Jaguar Health shares jumped 5.19% after hours following FDA fee waivers for two of its commercialized therapies.
JAGX, IONQ, VKTX, XNDU, GRAB were among the stocks seen trending on Tuesday, Sept. 22, 2026.
Gainers Jaguar Health (NASDAQ:JAGX) shares moved upwards by 32.2% to $45.56 during Tuesday's after-market session. The company's market cap stands at $1.1 million. Bullfrog AI Hldgs (NASDAQ:BFRG) shares
Gainers Jaguar Health (NASDAQ:JAGX) stock increased by 304.5% to $10.8 during Tuesday's regular session. The company's market cap stands at $1.1 million. Greenland Mines (NASDAQ:GRML) shares moved upwards by
Company remains sharply focused on its ongoing rare disease intestinal failure global development program for microvillus inclusion disease (MVID) and SBS for crofelemer powder for oral solution, targeting an NDA filing for MVID mid-2027SAN FRANCISCO, CA / ACCESS Newswire / September 22, 2026 / (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today announced that the U. Food and Drug Administration (FDA) has granted Napo's request for a waiver of the fee associated with the Pres
The Company's Common Stock will begin trading on a split-adjusted basis when the market opens on the Effective Date and will remain listed on The Nasdaq Capital Market under the symbol "JAGX". The new CUSIP number for the Company's Common Stock following the reverse stock split is 47010C854.
The trial is ongoing at multiple centers in the United States, the European Union, and the United Arab Emirates. This trial is expected to support a New Drug Application (NDA) filing for the treatment of the MVID indication in mid-2027.
The non-prescription digestive-support product extends Jaguar Health’s Neonorm franchise into the companion-animal market, with additional online and retail distribution expected shortly. Key Investor TakeawaysJaguar Health (NASDAQ:JAGX) has launched Neonorm Dog on Amazon as part of the commercial rollout of its new non-prescription animal-health product.
Napo remains sharply focused on its ongoing global development program for oral crofelemer as adjunctive therapy to parenteral support (PS) for pediatric rare IF diseases, including microvillus inclusion disease (MVID) and short bowel syndrome with IF (SBS-IF). In June 2026, as announced, data was presented at the 58th Annual European Society for Pediatric Gastroenterology, Hepatology & Nutrition (ESPGHAN) Meeting in Lille, France from ongoing investigational studies with oral liquid crofelemer
This is the newest page. Registered accounts read further back.